Abstract

Colon cancer-associated transcript 2 (CCAT2) is an intensively studied lncRNA with important regulatory roles in cancer. As such, cumulative studies indicate that CCAT2 displays a high functional versatility due to its direct interaction with multiple RNA binding proteins, transcription factors, and other species of non-coding RNA, especially microRNA. The definitory mechanisms of CCAT2 are its role as a regulator of the TCF7L2 transcription factor, enhancer of MYC expression, and activator of the WNT/β-catenin pathway, as well as a role in promoting and maintaining chromosome instability through the BOP1–AURKB pathway. Additionally, we highlight how the encompassing rs6983267 SNP has been shown to confer CCAT2 with allele-specific functional and structural particularities, such as the allelic-specific reprogramming of glutamine metabolism. Additionally, we emphasize CCAT2’s role as a competitive endogenous RNA (ceRNA) for multiple tumor suppressor miRNAs, such as miR-4496, miR-493, miR-424, miR-216b, miR-23b, miR-34a, miR-145, miR-200b, and miR-143 and the pro-tumorigenic role of the altered regulatory axis. Additionally, due to its upregulation in tumor tissues, wide distribution across cancer types, and presence in serum samples, we outline CCAT2’s potential as a biomarker and disease indicator and its implications for the development of resistance against current cancer therapy regiments and metastasis.

Highlights

  • Smaller species of ncRNA are mainly represented by microRNA, which are considered to range between 19 and 25 nucleotides and are mainly involved in regulating gene expression post-transcriptionally, targeting specific mRNAs based on the presence of complementary seed sequences [2–5]

  • cancer-associated transcript 2 (CCAT2) interacts with the RNA binding protein (RBP) ELAVL1/HuR at the nuclear level, a key factor involved in mRNA stabilization, previously shown to promote proliferation, apoptosis, and differentiation in multiple types of cancer [108]

  • Shi et al showed that ELAVL1 knockdown decreased Agt5 expression, this effect being restored through CCAT2 upregulation. These findings indicate that CCAT2 promotes the proliferative processes by targeting miR-4496 and the activation of autophagy via, and interacting with ELAVL1, and downregulating Agt5. [69]

Read more

Summary

Introduction

While the existence of non-coding species of RNA has been acknowledged for several decades already, the advent of modern sequencing techniques has allowed their detailed characterization and classification. The lncRNA HOTAIR, initially highlighted as a trans epigenetic regulator [12] of the key developmental HOX genes through its direct in different developmental [8,9] and pathological processes [10,11], which indicated their high functional variability. MYC is one of the downstream targets of the Wnt/β-catenin pathway, highlighting the dual potentiating role of CCAT2 in this tumor-promoting feedback loop. High WISP1 levels stimulate the expression of its effectors VEGF-A, MMP2, and ICAM-1, with important roles in angiogenesis, epithelial-to-mesenchymal transition (EMT) and metastasis [26] This interplay between CCAT2, MYC, and WNT molecules has been explored and confirmed in multiple cancers in recent years and is responsible for the main pro-tumorigenic roles of CCAT2. Similar studies confirmed the presence of the mechanism in the case of thyroid [27], ovarian [28], clear cell renal cell carcinoma [29], and breast cancers [30]

Allele-Specific Metabolic Reprogramming
Chromosomal Instability
RNA Editing and CCAT2-Associated RNA–DNA Differences at the rs6983267 Locus
Therapeutic Resistance
CCAT2 Enhancer Activity and Interactions with RBPs
CCAT2 as a Potential Biomarker
Findings
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call